Key Takeaways
- FY25 was a year of consolidation: Revenue degrew 4.7% as a favorable FY24 product mix, exchange rates and raw material costs did not repeat, and management describes the business as "not really fully in control of our numbers."
- Unit 3 is the near-term growth engine: A new production block has been capitalized, product validations are underway, and commercial supplies are expected to start in FY26, with management expecting a quick ramp-up.
- CMS pipeline is deepening: One molecule was commercialized in FY25 as a second source to a non-Indian supplier, another is expected in FY26, and management sees opportunities to commercialize "almost every year" looking at FY25–FY29.
- Peptide capabilities are being built at scale: A ₹300 crore investment is creating large-scale manufacturing in Unit 1, the first U.S. DMF (Difelikefalin) has been filed, and 10–15 peptide projects are in the pipeline.
- What to watch next quarter: Whether Unit 3 commercial supplies actually begin and ramp on schedule, the pace of the FY26 molecule commercialization, and any margin recovery from the suboptimal FY25 levels.
FY25 Performance: The Consolidation Year
- Revenue degrew 4.7% as the highly optimized FY24 conditions (favorable exchange rates, raw material costs, product mix) did not repeat; management calls FY24 margins a "North Star," not a benchmark.
- Gross margin contracted to 56.3% from 58.8% in Q4 FY24, driven by business mix, a decreased revenue base, and deleveraging that made margins suboptimal.
- CMS had a significant down year because molecules that contributed in FY24 did not contribute at the same level in FY25, reflecting the natural life cycle of products in the portfolio.
- GDS specialty volumes were uneven due to the small-volume nature of products like ophthalmic APIs; quarter-to-quarter lumpiness is inherent.
- Pre-registration pipeline products carry uncertainty: some are waiting on customer NDA approvals, while others are second-source additions that can take much longer to reach scale, or may never reach scale at all.
Saharsh Davuluri: "Our business is uneven due to the inherent nature of the CDMO business as well as the specialty GDS business, which is focused on small volume products. As a result, evaluating Neuland's trajectory on a 3-year block basis is perhaps a more accurate measure than comparing quarter-to-quarter or even an annual basis."
Unit 3: The Immediate Growth Catalyst
- New production block capitalized: An additional production block in Unit 3 has been capitalized, with product validations ongoing and commercial production expected to start in FY26.
- Quick ramp-up expected: Management expects no big gap between starting commercial supplies and the ramp-up; Unit 3's contribution has already started rising as products ramp.
- Unit 3 was dormant for years until CMS products were added; with December 2023 assets now coming in line, further ramp-up is expected, though the unit will eventually get saturated due to limited additional capacity.
- Capacity utilization context: The 30% to 40% figure previously discussed was for Unit 3's small-molecule capacity, not for peptides.
- Growth sequencing: Unit 3 will drive growth for the immediate period (maybe the next couple of years), after which Unit 1 may take over as the growth driver, though product mix will determine actual numbers.
CMS Pipeline: Second-Source Wins and Annual Commercializations
- One molecule commercialized in FY25: A commercially approved drug that has been on the market for a few years; Neuland qualified as a second supplier to a non-Indian first source, with commercial supplies starting shortly.
- Second molecule expected in FY26: Another molecule is expected to be commercialized during FY26, though management declined to specify the therapy area, timing within the year, or the size of the opportunity.
- Annual commercialization visibility: Management believes they will have opportunities to commercialize molecules almost every year, with big molecules commercializing annually, looking at FY25 through FY29.
- Long-term supply agreements are in place for all CMS molecules, providing contractual visibility.
- Geopolitical tailwinds: Biotech companies moving away from China are sending Phase I/Phase II projects to Neuland; occasionally, Phase III or near-commercial drugs seek Neuland as a secondary supplier, which can start commercial revenue sooner.
- Commercialization timing vs. revenue: The year a molecule gets commercialized may not be the year revenue contribution happens; FY26 growth indications are based on aggregate order values and business, not just the newly commercialized molecule.
Saharsh Davuluri: "But definitely, what I can share is that it is a commercially approved drug. It's been out in the market for a few years now. The first source is non-Indian source and Neuland is getting added as a second source."
Peptides and Technical Differentiation
- ₹300 crore peptide investment is directed toward creating very large-scale manufacturing capabilities in Unit 1 that currently do not exist at Neuland.
- First peptide DMF filed: A U.S. DMF for Difelikefalin has been filed, the company's first in the peptide space.
- 10–15 peptide projects are in the pipeline, making Neuland "a very obvious choice" for innovators seeking peptide API outsourcing in India.
- Deuterated API recognition: Neuland has one commercial deuterated molecule and several in the pipeline, establishing a differentiated position.
- Other technical strengths include chiral chemistry, hydrogenations, and targeted particle size distributions.
- Pipeline quality is improving year-on-year: Far more ₹100 crore+ CMS opportunities are entering the system today compared to 10 years ago.
Saharsh Davuluri: "The quality of projects that are entering the system every year, the overall quality is only improving. And if I have to illustrate that, let's say, if we say, okay, how many INR100 crore opportunities are entering the system? Maybe 10 years ago, we would barely see INR100 crore CMS opportunity. I think today, we see a far higher number of INR100 crore opportunities."
Margins: Suboptimal FY25, Recovery Expected but Unquantified
- FY24 margins were "highly optimized" due to favorable exchange rates, raw material costs, and product mix; management had always characterized them as a "North Star," not a benchmark.
- FY25 saw deleveraging that made margins suboptimal; more assets being capitalized will lead to more operating expenses going forward.
- Margins should go up from current levels, but management declined to give a range, calling FY24 levels hard to predict and keeping the outlook "vague."
- Management declined to provide EBITDA margin ballparks for FY26 or FY27 when asked directly by an analyst.
Saharsh Davuluri: "I think whatever we have seen in FY24, I think we had also indicated that those are highly optimized kind of margins, right? I think very favorable exchange rates, raw material costs, product mix, etcetera. We had always said that that's more like a North Star of our margins. We don't expect that to be like a basis or a benchmark."
Growth Outlook: FY26 Recovery, No Quantitative Guidance
- Growth trajectory expected to resume in FY26 on the FY24 base, with both CMS and GDS segments expected to grow, though more growth is expected from CMS as a percentage.
- Dual strategy in play: Focus on high-margin specialty business while increasing volumes for the Prime API business, both expected to see good growth in FY26.
- 20%–25% CAGR looking at FY27–FY29 is "something that's possible," per management, when asked if that rate is still achievable.
- Management declined to give quantitative growth guidance for FY26, citing the confidential nature of the business and limited ability to provide an outlook; investors would have to take an independent call.
- U.S. tariff impact unclear: Management has no clarity on potential U.S. tariffs at the moment and no imminent indication they are likely to come.
- U.S. revenue exposure: 30% of revenue is based on supplies to the U.S., not a 50-50 CMS/GDS split as an analyst had assumed.
Saharsh Davuluri: "It actually points to the reality of our business, right? I think it shows that we're not really fully in control of our numbers. And it is for those several factors that I had also reiterated in the opening remarks today. A small shift in the product mix could have an impact. Exchange rate, raw material costs, a lot of things can contribute to this. I think these are some of the reasons why I think these kind of fluctuations happen. And I think that's the reason why we also hesitate to give any kind of guidance."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Unit 3 commercial production | Product validations ongoing; commercial supplies to begin | FY26 |
| Unit 3 revenue momentum | Greater revenue momentum expected from commercialization of new production block | Latter half of FY26 |
| Growth trajectory resumption | Growth to resume on FY24 base | FY26 |
| New CMS molecule commercialization | One additional molecule to be commercialized | FY26 |
| CMS annual commercialization | Opportunities to commercialize molecules almost every year, with big molecules annually | FY25–FY29 |
| Peptide large-scale manufacturing | ₹300 crore investment in Unit 1 to create capabilities that currently do not exist at Neuland | On track (no date specified) |
| Margins direction | Margins should go up from suboptimal FY25 levels; range not given | FY26 |
Key Metrics
| Metric | Q4 FY25 |
|---|---|
| Total income | ₹335.8 cr, -14% YoY vs ₹390.4 cr |
| EBITDA | ₹58.2 cr, margin 17.3% vs ₹112.2 cr and 28.7% margin in Q4 FY24 |
| Gross margin | 56.3% vs 58.8% in Q4 FY24 |
| Profit after tax | ₹27.7 cr vs ₹67.6 cr in Q4 FY24 |
| EPS | ₹21.6 per share |
| FY25 total income | ₹1,497.3 cr, -4.7% YoY vs ₹1,571.1 cr |
| FY25 EBITDA (excl. exceptional items of ₹7.6 cr) | ₹342.8 cr vs ₹474.5 cr in FY24 |
| FY25 free cash flow | ₹111 cr |
| Net debt | Negative ₹29 cr (net cash position) |
| Working capital | 107 days of sales at end of March |
| CMS revenues (FY25) | ~₹637 cr, largely driven by commercial molecules |
| Revenue from supplies to U.S. | 30% of total revenue |
| CMS pipeline projects | 97 total projects, up from 81 in FY22 |
| CMS pre-registration molecules | 4, down from 6 QoQ |
| FY25 capital spends | ₹26.4 cr |